[easy website builder software] [web page software] []
[Team]
[R&D]
[homepage]
[R&D]
[Team]
[Pipeline]
[Investisseurs]
[contact]
[]
[]
[]
[]
[]
[]
[]

The company ElyssaMed   is established at the end of 2015 with the support from l'Institut Gustave Roussy, coming as shareholder.

12.18.2015

The Dark Side of Immuno-Oncology

The company ElyssaMed   is located now at the 1st Paris Bio-incubateur : Parisbiotech Santé, which is established at Cochin Hospital (APHP).

Home page

Elyssamed SAS all rights 2015-2016

The project is supported by:

Accueil

ElyssaMed sas

Project display

The company

ElyssaMed® is a spin-off of Gustave Roussy Institute and will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant.


This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and  lead to their destruction.

  

welcome

The founder

Fathia MAMI-CHOUAIB, project director.

Research director at INSERM Normale, Fathia Mami-Chouaib obtained a PhD in immunology from the Pasteur Institute in Paris in 1984.


After a 3-year post-doctoral fellowship at NIH, Bethesda, USA, she was recruited to INSERM to continue her research at Gustave Roussy Institute.

Characteristics

Team display

Deposit of the 1st patent related to technology by the Institut Gustave Roussy, The university Paris SUD and INSERM.

06.19.2008

06.15.2014

Awards: Natioanal business creation and innovative technologies awardfrom the French Ministry of Education and Research.

ElyssaMed SAS was winner in the category "emerging companies".

  

06.18.2015

News

Awards: Natioanal business creation and innovative technologies awardfrom the French Ministry of Education and Research. 

ElyssaMed SAS was nominated in the I-LAB category "creation/development" with recognition of the company's seriousness and scientific credibility.

 

05.01.2016